Xenetic Biosciences, Inc. XBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-66.61
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $3.0M | -$2.7M | — | — | $7.4M |
| 2024 | $2.5M | -$4.0M | — | — | $6.0M |
| 2023 | $2.5M | -$4.1M | — | — | $9.8M |
| 2022 | $1.7M | -$6.6M | — | — | $13.6M |
| 2021 | $1.2M | -$5.6M | — | — | $18.4M |
| 2020 | $436,942 | -$10.9M | — | — | $12.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| PARSLOW JAMES F | Interim CEO and CFO | 2026-04-21 | Grant | 100,000 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -66.61 (distress)
- Working capital / assets 0.847
- Retained earnings / assets -23.898
- EBIT / assets -0.339
- Equity / liabilities 7.64
Source: SEC EDGAR filings · CIK 0001534525 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.